Advice

in the absence of a submission from the holder of the marketing authorisation:

azacitidine (Vidaza®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of adult patients aged 65 years or older who are not eligible for haematopoietic stem cell transplantation (HSCT) with acute myeloid leukaemia (AML) with >30% marrow blasts according to the World Health Organisation (WHO) classification.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice110KB (PDF)

Download

Medicine details

Medicine name:
azacitidine (Vidaza)
SMC ID:
1175/16
Indication:
Treatment of adult patients aged 65 years or older who are not eligible for haematopoietic stem cell transplantation (HSCT) with acute myeloid leukaemia (AML) with >30% marrow blasts according to the World Health Organisation (WHO) classification.
Pharmaceutical company
Celgene Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published
11 July 2016